Listing Department
As filed · Press Release
EarningsNotablemateriality 70 out of 100
What happened
FactListing Department.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Margins
DelayedEarlierQ4 FY26
In Q4 FY26, RPG Life Sciences recorded a 23.6% Y-o-Y increase in revenue, along with a healthy EBITDA margin of 25.6%.
NowQ1 FY27
Revenue grew 15.8%, EBITDA by 17.9% and margins by 40 bps y-o-y in Q1 FY27
Change
FactTimeline delay
Implication
CapitSignal interpretationThe stated timeline moved by 1 quarter(s) (earlier to later). The stated figure moved -33.05%.confidence 60%
Watch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- On the back of continued robust performance, The Board of Directors has recommended highest ever dividend of 2 (management committed by FY25)
- The Board of Directors at its meeting held today has recommended a Final dividend of Rs 24 per equity share i. (management committed by FY26)
Evidence
- press release for the quarter and year ended on 31st March 2025(opens the original filing in a new tab)
- Earlier statement · Q4 FY26
- Latest statement · Q1 FY27
- Earlier statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +2 corroborating keywords; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%